THYMALIN [10mg]

$50.00

Thymalin is a multi-component polypeptide extract from calf thymus, studied mainly in Russian research for immune regulation and thymic support. Its human evidence is limited and has not been widely replicated in large independent trials. A research-grade vial is not equivalent to a regionally approved pharmaceutical product.

RESEARCH USE ONLY Laboratory research
BATCH DOCUMENTATION Not currently available
PRODUCT FORMAT 10 mg Ā· Lyophilized powder

For laboratory research only. Not for human or animal consumption.

Category:

VIP Peptides Ā· Research Compound

Thymalin Research Profile

Thymalin is a polypeptide complex extracted from bovine thymus tissue.
Associated with the Russian bioregulator research tradition, it is a
multi-component extract rather than a single defined synthetic peptide.
This profile covers research-grade material.

Bovine Thymus
Source described in supplied information
Multi-Component
Polypeptide extract
Immune Research
Primary research area
Research Vial
Not an FDA-approved product

Product Information

About Thymalin

Unlike a single-sequence synthetic peptide such as Thymosin
Alpha-1, Thymalin is described as a complex of short peptides
isolated from calf thymus. The supplied information mentions
dipeptides such as EW (Glu-Trp) and KE.

Proposed research actions include effects on T-cell maturation
and differentiation, CD4/CD8 balance, innate and adaptive immune
activity, and cytokine signaling. These proposed actions do not
establish clinical effectiveness.

Research Overview

Product Thymalin
Source Bovine thymus tissue
Product type Multi-component polypeptide extract
Source vial size Commonly described as 10 mg
Research tradition Russian peptide bioregulator research
US regulatory status Not FDA-approved for any indication

Evidence & Research

What Research Has Examined

T-Cell Development

Laboratory and clinical literature has examined T-cell
differentiation and maturation, including changes in markers
associated with mature T cells. Some studies also report changes
in immune parameters such as CD4/CD8 ratios.

Immune Regulation

Proposed research effects include modulation of innate and
adaptive immune activity and cytokine production, including
support for some Th1-type responses and changes in certain
pro-inflammatory signals.

Clinical Use Reported in Russia

Russian clinical literature describes use in contexts including
immune dysfunction, chronic infections, recovery after
chemotherapy or radiation, and age-related immune decline.
These reports do not establish effectiveness for those conditions
under independent, large-scale trials.

COVID-19 Research

A small Russian clinical study reported changes in inflammatory
markers, including IL-6, CRP and D-dimer, when Thymalin was added
to standard care. This finding is preliminary and does not
establish it as a COVID-19 treatment.

Long-Term Observational Findings

Russian observational research in older adults, sometimes involving
Thymalin alongside Epitalon or Epithalamin, has reported lower
all-cause mortality over multi-year follow-up. One often-cited
cohort reported an approximately twofold difference; observational
findings cannot establish that Thymalin caused the difference.

Infection & Geroprotective Signals

Russian literature also reports changes in immune measures,
infection rates and broader geroprotective outcomes. Lifespan
extension and broad anti-aging effects remain preliminary claims.

Evidence Limitations

Interpret Findings with Caution

Much of the available clinical literature comes from Russia and is
associated with a limited number of research groups. Evidence
includes observational and open-label reports, with independent
replication in large, rigorous Western trials lacking.

Some long-term reports involved other thymic or pineal products in
combination. They should not be interpreted as proof that Thymalin
alone extends lifespan or produces broad anti-aging effects.

Safety & Regulatory Status

Important Limitations

Thymalin is described as generally well-tolerated in available Russian
clinical reports; mild injection-site reactions are among the effects
noted. The published evidence is not sufficient to establish long-term
safety, and serious-event reporting in limited studies should not be
treated as proof of safety.

Thymalin is not FDA-approved for any indication in the United States.
The FDA has identified a Thymalin product marketed in the United States
as an unapproved new drug.

The supplied information reports that a Thymalin pharmaceutical product
is used in Russia for certain indications. Approval of a particular
regional pharmaceutical product does not apply to research-grade
material, which can differ in composition, manufacturing controls and
quality.

For laboratory research only. Not intended for human or animal
consumption, clinical use, diagnosis, treatment, cure, mitigation or
prevention of disease.

Reviews

There are no reviews yet.

Be the first to review “THYMALIN [10mg]”

Your email address will not be published. Required fields are marked *

Scroll to Top